☆ 4.5 Article

CAR-T Cells and the Kidney: Insights from the WHO Safety Database

BIODRUGS (2023)

Related references

Note: Only part of the references are listed.

Letter Hematology

Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells

Adam Goldman et al.

BLOOD (2023)

Add to Collection

Review Urology & Nephrology

Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy

Nupur N. Uppal et al.

Summary: Novel immunotherapy drugs have revolutionized cancer medicine, but they can also lead to immune-related adverse events, including electrolyte disorders. This review examines the associated electrolyte disorders, such as hyponatremia, hypokalemia, hypercalcemia, hypocalcemia, and hyperphosphatemia. Early recognition and prompt diagnosis are crucial for managing these novel electrolyte disorders.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Add to Collection

Review Oncology

Engineered T Cells: CAR T Cell Therapy and Beyond

P. Connor Johnson et al.

Summary: This review article discusses the current state and future directions of engineered T-cell therapies in non-Hodgkin lymphomas. It provides an overview of the approved CAR T-cell products and other promising engineered T-cell products in development. CAR T-cell therapies have significantly transformed the treatment landscape for relapsed/refractory B cell lymphomas and hold great promise for future clinical use.

CURRENT ONCOLOGY REPORTS (2022)

Add to Collection

Article Urology & Nephrology

Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report

Tristan de Nattes et al.

Summary: Post-transplant lymphoproliferative disorder is a complication of kidney transplantation. Anti-CD19 CAR T-cell therapy may be used as a treatment option. This case report describes a kidney transplant recipient who developed lymphoma post-transplantation and received anti-CD19 CAR T-cell therapy after chemotherapy failed. The kidney transplant function improved after treatment, but the lymphoma progressed and led to the patient's death.

AMERICAN JOURNAL OF KIDNEY DISEASES (2022)

Add to Collection

Review Immunology

Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases

Manqiqige Su et al.

Summary: This study reviewed the developments of CAR-based therapies in autoimmune diseases and provided future perspectives on optimizing the performance of CAR-based therapies.

AUTOIMMUNITY REVIEWS (2022)

Add to Collection

Article Urology & Nephrology

Acute Kidney Injury in Critically Ill Patients with Cancer

Shruti Gupta et al.

Summary: Critically ill cancer patients have a higher incidence of acute kidney injury treated with renal replacement therapy. Acute kidney injury can be a direct or indirect result of cancer itself, its treatment, or complications. Recent studies show that having an underlying cancer is no longer a contraindication for initiating renal replacement therapy or advanced life-supportive measures. However, these results should not be used to justify unrealistic perseverance or deny palliative care in desperate cancer patients. The decision to initiate advanced therapy should consider the patient's long-term prognosis and quality of life.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Add to Collection

Review Critical Care Medicine

Severe infections in recipients of cancer immunotherapy: what intensivists need to know

Adrien Joseph et al.

Summary: Given the increasing number of cancer patients in the ICU and the importance of immunotherapy, intensivists will encounter patients with immunotherapy-related complications and infections. Different types of immunotherapy have varying risks of infection, with CAR T-cell therapy being associated with profound immunosuppression and checkpoint blockers being associated with increased infection risks when used with corticosteroids and immunosuppressive drugs. The T-cell engaging bispecific therapy, on the other hand, has fewer infectious adverse events. Intravesical administration of Bacillus Calmette-Guerin (BCG) can lead to disseminated BCGitis and severe sepsis.

CURRENT OPINION IN CRITICAL CARE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database

Michele Fusaroli et al.

Summary: This study aimed to characterize the safety profile of chimeric antigen receptor T-cell therapies by analyzing adverse drug reaction data. The results showed that cytokine release syndrome was a major adverse reaction, with most events occurring within the first 10 days of treatment. Additionally, unexpected associations were found, such as axi-cel with cardiomyopathies and gastrointestinal perforations, and tisa-cel with hepatotoxicity and pupil disorders.

DRUG SAFETY (2022)

Add to Collection

Review Cell Biology

Acute Kidney Injury in Cancer Immunotherapy Recipients

Adrien Joseph et al.

Summary: Cancer immunotherapy can lead to acute kidney injury, with cytokine release syndrome, tumor lysis syndrome, sepsis, acute tubular interstitial nephritis and glomerular diseases being the main causes. The mechanisms, prognosis and treatment of renal damage in these contexts have been described, although the pathophysiology remains mostly elusive.

CELLS (2022)

Add to Collection

Letter Urology & Nephrology

Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel

Meghan D. Lee et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

Add to Collection

Review Cell & Tissue Engineering

CAR T cells in solid tumors: challenges and opportunities

Faroogh Marofi et al.

Summary: CAR T cells have shown significant advancements in treating blood disorders, but face challenges in solid tumor therapy due to issues with recognition, trafficking, and survival within the tumor. Efforts to overcome these challenges, including addressing the immunosuppressive tumor microenvironment, show promise in reducing T cell exhaustion and improving therapeutic outcomes in non-hematologic malignancies.

STEM CELL RESEARCH & THERAPY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice

Giulia Bonaldo et al.

Summary: The two CAR-T therapies, axicabtagene ciloleucel and tisagenlecleucel, approved in the US and EU have shown good efficacy but the major issue remains cytokine release syndrome (CRS). Despite no new adverse drug reactions (ADR) being revealed, the balance between effectiveness and safety profile of CAR-T therapies still needs further investigation.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Review Urology & Nephrology

Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies

Swetha R. Kanduri et al.

KIDNEY INTERNATIONAL REPORTS (2021)

Add to Collection

Article Hematology

Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study

Charles Dolladille et al.

Summary: CAR-T therapy can lead to various adverse drug reactions (ADRs), including cytokine release syndrome, neurological disorders, and hematological disorders. Some ADRs may result in fatalities. Infections, hemophagocytic-lymphohistiocytosis, and end organ failures including neurological or lung complications should be carefully monitored.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Review Oncology

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains

Kathryn M. Cappell et al.

Summary: CAR T cell therapies targeting haematological malignancies show promising efficacy, with CD28- and 4-1BB-derived costimulatory domains demonstrating potentially different cellular and clinical effects. Further research is needed to compare their effectiveness and toxicity profiles.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Urology & Nephrology

Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma

Shruti Gupta et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2020)

Add to Collection

Article Hematology

Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery

Victoria Gutgarts et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

Add to Collection

Article Urology & Nephrology

Correlation of IL-6 secretion and hyponatremia with the use of CD19+chimeric antigen receptor T-cells

Brianne N. Dixon et al.

CLINICAL NEPHROLOGY (2020)

Add to Collection

Article Biology

Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance

Goeun Park et al.

LIFE-BASEL (2020)

Add to Collection

Article Oncology

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

Kitsada Wudhikarn et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Article Chemistry, Medicinal

Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety Data

Concetta Rafaniello et al.

PHARMACEUTICALS (2020)

Add to Collection

Article Hematology

Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management

Martina Pennisi et al.

BLOOD ADVANCES (2020)

Add to Collection

Review Hematology

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

Jennifer N. Brudno et al.

BLOOD REVIEWS (2019)

Add to Collection

Article Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Frederick L. Locke et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Editorial Material Urology & Nephrology

Chimeric Antigen Receptor T Cell Therapy and the Kidney What the Nephrologist Needs to Know

Kenar D. Jhaveri et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)

Add to Collection

Review Urology & Nephrology

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future

Mark A. Perazella et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)

Add to Collection

Article Urology & Nephrology

Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease

Karina Durlacher-Betzer et al.

KIDNEY INTERNATIONAL (2018)

Add to Collection

Review Medicine, General & Internal

Chimeric Antigen Receptor Therapy

Carl H. June et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Joe-Elie Salem et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

First-Ever CAR T-cell Therapy Approved in U.S.

Cancer Discovery (2017)

Add to Collection

Review Hematology

Chimeric antigen receptor T-cell therapies for multiple myeloma

Lekha Mikkilineni et al.

BLOOD (2017)

Add to Collection

Article Immunology

Polyomavirus BK Viremia in Kidney Transplant Recipients After Desensitization With IVIG and Rituximab

Debora Barbosa et al.

TRANSPLANTATION (2014)

Add to Collection

Article Urology & Nephrology

Notice

Kidney International Supplements (2012)

Add to Collection

Article Medicine, General & Internal

Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia

David L. Porter et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Hematology

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

James N. Kochenderfer et al.

BLOOD (2010)

Add to Collection

Review Public, Environmental & Occupational Health

Quantitative signal detection using spontaneous ADR reporting

A. Bate et al.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)

Add to Collection

Review Urology & Nephrology

A review of drug-induced hyponatremia

George Liamis et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.